ULCERATIVE COLITIS

This study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …

This study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…

This study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…

This study looks at whether taking a common ulcerative colitis medication (5-ASA) at a specific time of day—morning or evening—can better reduce hidden inflammation. Thirty-two adults with inactive UC will try both timing schedules over three months. Researchers will measure infl…

This study tests guselkumab, a drug that targets inflammation, in over 1,000 people with moderate to severe ulcerative colitis. Participants receive either guselkumab or a placebo to see if the drug can improve symptoms and lead to remission. The goal is to find a new treatment o…

This study compares two approved drugs, risankizumab and vedolizumab, in about 530 adults with moderate to severe ulcerative colitis who have not tried targeted therapies before. Participants will receive one of the two drugs for about a year. The main goal is to see which drug b…

This study looks at the long-term safety of filgotinib, a drug for ulcerative colitis, in over 1,100 adults who already took part in a filgotinib trial. The main goal is to track side effects and lab test changes over time. Participants must have completed a prior filgotinib stud…

This study tests an oral medication called upadacitinib in children aged 2 to 17 with moderate-to-severe ulcerative colitis who have not improved with standard treatments. The goal is to see if the drug can reduce inflammation and control symptoms like diarrhea and bleeding. Part…

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants had already taken part in earlier studies and will continue taking etrasimod for up to 2 years. The goal is to see if the drug can …

This Phase 2a trial is testing an injectable biologic drug called ALTB-268 in 50 adults with moderately to severely active ulcerative colitis that has not improved with other biologic therapies. The study is open-label, meaning everyone receives the drug, and will measure changes…

This study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. Participants take either the drug or a placebo for 12 weeks, then everyone gets the drug for up to a year. The goal is to see if TAK-279 reduces bowel inflammation…

This study tests the long-term safety and effectiveness of an experimental drug called ABX464 in people with moderate to severe ulcerative colitis. Participants who previously improved on ABX464 in earlier studies will continue taking it daily for up to 54 months. Researchers wil…

This study tests whether adding high-dose vitamin D3 to standard anti-TNF therapy can improve symptoms and reduce inflammation in people with active Crohn's disease or ulcerative colitis. About 100 adults starting anti-TNF treatment will receive either vitamin D3 or a placebo for…

This study tests a support program for teens aged 16-17.5 with Crohn's disease or ulcerative colitis as they move from pediatric to adult healthcare. The program includes personalized assessments, a transition navigator, and virtual skill-building sessions. Researchers will measu…

This study looks at whether the probiotic VSL#3 can change how bile acids work in people with Crohn's disease or ulcerative colitis. About 79 participants will take two sachets of VSL#3 daily for six weeks. Researchers will measure bile acid levels in blood and stool to see if th…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue treatment. The goal is to see if the drug can keep…

This study tests whether a fecal transplant (FMT) can safely and effectively treat recurrent C. difficile infections in children, including those with inflammatory bowel disease (IBD). Researchers will give FMT to 250 children aged 3-21 and track whether the infection comes back.…

This study tests an experimental drug called emvistegrast (GS-1427) in about 228 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo, and researchers check if symptoms improve after 12 weeks. The goal is to see if the drug can redu…

This phase 3 trial tests a drug called tulisokibart (MK-7240) in about 1,020 people with moderate-to-severe ulcerative colitis. The drug is a lab-made antibody given by IV or injection. The goal is to see if it can help people achieve and maintain remission (fewer symptoms and le…

This study tests whether using a computer dashboard to guide infliximab dosing is more effective and safer than standard dosing for people with Crohn's disease or ulcerative colitis. About 124 participants will receive either dashboard-guided or standard treatment, with the goal …

This study tests a digital health system that reminds people with inflammatory bowel disease (IBD) to take their medication and lets them report symptoms. About 123 adults starting a new oral or injectable treatment will use the system or get standard care for 12 months. The goal…

This pilot study tests whether a plant-based resistant starch, tailored to each child's gut bacteria, can improve gut health in 80 children with Crohn's disease or ulcerative colitis. Participants will take the starch or a placebo for a period, and researchers will measure change…

This study tests whether a plant-based starch, tailored to each child's needs, can help restore a healthier gut microbiome in children with inflammatory bowel disease (Crohn's or colitis). About 100 children with mild disease or in remission will receive the starch for 6 months. …

This early-stage study tests whether delivering a patient's own stem cells directly into the artery that supplies the colon is safe for people with moderate to severe ulcerative colitis. Twenty adults who have not responded to at least two standard treatments will receive one dos…

This phase 2 trial tests Aquamin, a mineral supplement made from red marine algae, in 40 people with mild ulcerative colitis or those in remission. Researchers want to see if it improves symptoms, reduces inflammation, and helps maintain remission. Participants take 4 capsules da…

This study tests whether transplanting healthy donor stool into the gut can help people with ulcerative colitis, a chronic bowel disease. About 150 adults with active or steroid-dependent disease will receive either real fecal transplants or a sham procedure. The goal is to see i…

This study looks at whether a gluten-free diet can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in symptoms, gut bacteria, and lab results in 60 adults over time. The goal is to see if avoiding gluten c…

This study aimed to test whether MitoQ, a dietary supplement with antioxidant properties, could help control inflammation in children aged 6–17 with mild-to-moderate ulcerative colitis. Participants would have taken MitoQ or a placebo daily for 24 weeks alongside their usual medi…

This study follows 509 adults with moderate to severe ulcerative colitis who are starting filgotinib, a drug also known as Jyseleca. Researchers want to see how long people stay on the treatment, how well it controls symptoms, and how it affects quality of life in everyday medica…

This study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard steroid drugs helps people with severe ulcerative colitis get better faster. About 44 adults with acute severe colitis will be randomly assigned to receive eithe…

This phase 3 trial tests whether a daily pill called ABX464 (obefazimod) can help people with moderate-to-severe ulcerative colitis stay in remission. Over 1,100 participants who completed an earlier induction study will receive either 25 mg, 50 mg, or a placebo for 44 weeks. The…

This study tests a new drug called lutikizumab in about 156 adults with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. Participants receive either lutikizumab or adalimumab (Humira) for 12 weeks, then continue based on response.…

This study tests a new drug called rosnilimab in 132 adults with moderate to severe ulcerative colitis. The goal is to see if it can reduce disease activity and improve symptoms compared to a placebo. Participants must have tried other treatments without success. The trial is act…

This study tests whether two special diets—the specific carbohydrate diet or an elemental (liquid) diet—can help people with active Crohn's disease or ulcerative colitis feel better. Forty adults will choose one diet and follow it for 6 weeks, while researchers track symptoms, in…

This early-phase study tests CP101, an oral capsule made from healthy donor stool, in 30 adults with mild-to-moderate ulcerative colitis. The goal is to see if the drug can safely restore a healthy gut microbiome and improve symptoms. Participants receive either a short or extend…

This study tests fecal microbiota transplantation (FMT) in 30 people with mild-to-moderate ulcerative colitis. Participants receive donor stool either through a colonoscopy or as capsules at weeks 0 and 4. The goal is to see if FMT can help achieve steroid-free remission and impr…

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a per…

This study tests whether listening to jazz or reggae music can reduce chronic pain in people with IBS, Crohn's disease, or colitis. Researchers will compare two groups: one listens to mindful jazz, the other to reggae, over four weeks. The goal is to find a safe, non-addictive wa…

This study tests whether personalized exercise coaching can reduce fatigue and improve quality of life in children with inflammatory bowel disease (IBD). Seventy children will be split into two groups based on their current exercise habits and will follow a 24-week program with a…

This study looks at whether regular text message check-ins and the ability to text your IBD care team can improve disease management and quality of life. About 900 people with Crohn's disease or ulcerative colitis will take part. Some will get extra symptom surveys and texting ac…

This registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…

This study follows nearly 5,000 children with Crohn's disease, ulcerative colitis, or indeterminate colitis to monitor the long-term safety of their treatments, including the drug infliximab. Researchers collect information on side effects, disease activity, and quality of life o…

This study looks at whether taking extra random biopsies during a colonoscopy helps find precancerous growths in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 1,600 participants will be randomly assigned to one of two biopsy…

This study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works,…

This study observes 1006 adults with ulcerative colitis or Crohn's disease in Brazil who are taking or have taken vedolizumab. Researchers will look at how long patients stay on the drug and what other treatments they used before. No new treatment is given—this is just a review o…

This study observes how 4,000 adults with ulcerative colitis are treated in real-world clinics, not in a controlled trial. Researchers will analyze prescription patterns and outcomes to create an updated treatment flowchart. The goal is to improve understanding of which therapies…

This study is testing a special thermal probe that measures temperature changes in the lining of the colon during a routine colonoscopy. The goal is to see if the probe can detect inflammation in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerati…

This 5-year observational study is following 15,000 adults and children with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, in real-world clinics. Researchers are collecting data on disease patterns, treatment use, and patient outcomes to bett…

This study looks at whether continuous heart rate variability (HRV) monitoring can predict how well patients with inflammatory bowel disease (IBD) respond to biologic therapies like infliximab or vedolizumab. Researchers will track HRV in 100 patients starting treatment and compa…

This observational study is following up to 500,000 adults with chronic gastrointestinal diseases like Crohn's disease, ulcerative colitis, and eosinophilic GI disease. Researchers will collect data from electronic health records and patient reports to understand how these condit…

This study observes 562 adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are starting or switching to Hyrimoz®, a biosimilar of adalimumab. Researchers will track how many patients continue the treatment after 6 months and why some stop, such as …

This registry is following over 2,200 adults with inflammatory bowel disease (IBD) across North America to see how approved treatments work in everyday practice. Researchers are collecting data on disease patterns, complications, and patient outcomes. The goal is to better unders…